Historical Parallels

Watch your back.

Send me real-time posts from this site at my email

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. 

Mylan: Pipeline Update, Patent Challenge

Mylan N.V. MYL 0.54% is scheduled to hold its investor day in New York City on April 11. The company is expected to shed light on the following: 

  • A recently announced biosimilar Botox program with Revance Therapeutics Inc RVNC 0.73%.
  • A Humira biosimilar program.
  • Its platform and pipeline.

A U.S. Patent Trial and Appeal Board oral hearing for Allergan plc Ordinary Shares AGN 1.69%'s Restasis is scheduled for April 3. The PTAB denied St. Regis Mohawk Tribe's motion to terminate Mylan'sRestasis challenge over six Restasis-related patents, according to a Feb. 26 release from Mylan.

A final decision on the challenged patents is scheduled for June 6. Source

Weak upside still holds.

$MYL, Mylan N.V. / D